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ABSTRACT 
The proto-oncogene PTTG and its binding partner PBF have been widely studied in multiple 
cancer types, particularly thyroid and colorectal, but their combined role in tumourigenesis is 
uncharacterised. Here, we show for the first time that together PTTG and PBF significantly 
modulate DNA damage response (DDR) genes, including p53 target genes, required to 
maintain genomic integrity in thyroid cells. Critically, DDR genes were extensively repressed 
in primary thyrocytes from a bitransgenic murine model (Bi-Tg) of thyroid-specific PBF and 
PTTG overexpression. Irradiation exposure to amplify p53 levels further induced significant 
repression of DDR genes in Bi-Tg thyrocytes (P=2.4x10-4) compared to either PBF- 
(P=1.5x10-3) or PTTG-expressing thyrocytes (P=NS). Consistent with this, genetic instability 
was greatest in Bi-Tg thyrocytes (mean GI index of 35.8±2.6%), as well as significant 
induction of gross chromosomal aberrations in thyroidal TPC-1 cells following 
overexpression of PBF and PTTG. We extended our findings to human thyroid cancer using 
TCGA datasets (n=322) and found striking correlations with PBF and PTTG expression in 
well-characterised DDR gene panel RNA-seq data. In addition, genetic associations and 
transient transfection identified PBF as a downstream target of the RTK-BRAF signalling 
pathway, emphasising a role for PBF as a novel component in a pathway well-described to 
drive neoplastic growth. We also showed that overall survival (P=1.91x10-5) and disease-free 
survival (P=4.9x10-5) was poorer for TCGA patients with elevated tumoural PBF/PTTG 
expression and mutationally activated BRAF. Together our findings indicate that PBF and 
PTTG have a critical role in promoting thyroid cancer that is predictive of poorer patient 
outcome. 
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INTRODUCTION 
The world-wide incidence of thyroid cancer has risen sharply in the past decade1 with an 
estimated 637,115 people living with the disease in the US in 2013. The 5-year survival rate 
of papillary thyroid carcinomas (PTCs) is high at 98.1%; however PTCs can differentiate into 
more aggressive and lethal thyroid cancers especially in individuals aged >45 years.2 In 
addition, recurrence of thyroid cancer has been estimated at up to nearly 30% of cases.3 
Recent progress in large scale multi-platform studies has identified 96.5% of oncogenic 
drivers in PTCs.4 The emerging complexity in molecular subtypes of PTCs however, with 
four newly-identified subgroups of BRAF-mutant tumours,4 represents a significant challenge 
in developing targeted therapies based on genomic insight. A better understanding will be 
needed of interactions between key effectors of tumourigenesis that influence molecular 
subgroups to enable development of effective treatments. 
Previous studies by our group5,6 and others7 implicated the proto-oncogene PTTG and its 
binding partner PBF in thyroid cancer but their precise roles in tumourigenesis remain 
relatively undefined. PTTG is the better characterised proto-oncogene and has been studied 
recently in a broad range of tumour types such as breast,8,9 colorectal10 and ovarian.11 In 
particular, PTTG is a complex, multifunctional protein involved in a wide range of processes 
such as cell cycle regulation, invasion, genetic instability, senescence and metabolism.8,10-14 
Also known as the human securin, PTTG ensures the meticulous segregation of 
chromosomes during mitosis,15 and both over- and under-expression cause genetic 
instability.16,17 The central functions of PTTG require its presence in the nucleus and yeast 2 
hybrid screening initially identified PBF, which contains a bipartite nuclear localisation 
signal, as a specific interacting partner of PTTG.18 Thus PBF became an obligate model of 
subcellular shuttling for PTTG, facilitating its nuclear transport.   
Also known as PTTG1IP, PBF had not been studied functionally before it was identified 
as a binding partner for PTTG. However, similar to PTTG, PBF demonstrates transforming 
ability and is overexpressed in a growing number of tumour types.6,19,20 PBF was recently 
identified as a central driver gene in human cancer as discerned across 34 tumour types via 
DOTS-Finder bioinformatic analysis.21 We initially highlighted a role for PBF in 
tumourigenesis as subcutaneous PBF overexpression in fibroblasts induced high-grade 
malignant tumour formation in athymic nude mice.6 However, a thyroid-specific transgenic 
model (PBF-Tg) showed significant hyperplastic thyroid growth but did not exhibit frequent 
tumours.22  
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Inactivation of the tumour suppressor protein p53 is a critical event in the pathogenesis of 
most cancers.23 Loss of p53 function, for instance, has been linked to genomic instability, 
insensitivity to apoptotic signals, invasiveness and altered cellular metabolism.24 The role of 
p53 in differentiated thyroid cancer (DTC) is unclear due to a very low prevalence (0.8%) of 
TP53 mutations.4 PTTG has been reported to bind directly to p53 and reduce the activity of 
p53-specific promoters,25 including p53-regulated transcription of PTTG-targeting miRNAs 
in pituitary cells.26 More recently, we identified PBF as a negative regulator of p53 in 
thyroid27 and colorectal cancer,28 with implications for impairing the DNA damage response 
(DDR) and increased tumour invasiveness. Given these observations, the relationship 
between PBF and PTTG warrants further investigation in vivo to determine the extent to 
which they interact to modulate the DDR, including the role of p53 target genes, and thus 
promote thyroid cancer progression.  
Our study now suggests that PBF and PTTG modulate DDR genes to significantly 
increase genomic instability - an underlying mechanism implicated in thyroid cancer 
progression. In particular, we provide extensive insight into DNA repair genes affected by 
PBF and PTTG in bi-transgenic mice, as well as in human thyroid cancer TCGA data. We 
further characterise genetic alterations associated with PBF and PTTG, which implicates PBF 
as a downstream target of the RTK-BRAF signalling pathway that drives neoplastic growth 
in multiple different cancer types. These findings have implications for using PBF and PTTG 
to identify patients with more aggressive thyroid cancer. 
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RESULTS                                 
Enlarged thyroids in a murine model of targeted induction of PBF and PTTG 
To investigate PBF and PTTG in thyroid cells, we constructed a bitransgenic model (Bi-Tg) 
of thyroid-specific PBF and PTTG over-expression by crossing two FVB/N murine models of 
human PBF (PBF-Tg) and PTTG (PTTG-Tg) transgenes under the control of the bovine 
thyroglobulin promoter (Figure 1a). Greater expression of PTTG did not appear to increase 
PBF protein levels and vice versa (Figure 1b). In keeping with previous data, expression of 
both proto-oncogenes was confined to the thyroid gland (Supplementary Figure S1a). 
Examination of body weight did not reveal any significant differences between Bi-Tg and 
wild-type (WT) mice (Supplementary Figure S1b).  
A striking phenotype of Bi-Tg mice was a significantly greater thyroid weight than in all 
other genotypes (Figure 1c). Bi-Tg thyroid glands, for instance, were up to 2.4-fold heavier 
than those of either PTTG-Tg or WT littermates (Figure 1c; P<0.001), and >50% heavier 
than in age-matched female PBF-Tg mice (Figure 1d; P<0.001). Indeed, simultaneous 
induction of both proto-oncogenes exceeded the additive effect expected from combined 
over-expression since the thyroid weight of PTTG-Tg mice was not significantly different 
compared to WT (Figure 1c and d). A distinctive characteristic of Bi-Tg mice was 
significantly reduced survival compared to WT (P<0.05), PBF-Tg (P<0.05) and PTTG-Tg 
(P<0.05) littermates up to 400 days of age (Figure 1e). No consistent physiological causes of 
this increased mortality were identified. 
In terms of thyroid function, the only significant alteration in serum TSH across genotypes 
and genders was in female PTTG-Tg mice compared to age- and sex-matched WT 
(Supplementary Figure S1c; P<0.05). Total T3 and T4 were induced in Bi-Tg and PTTG-Tg 
males (Supplementary Figures S1d and e), and total T3 was marginally higher in Bi-Tg 
females than WT females (Supplementary Figure S1d). However, the significantly altered 
thyroid sizes apparent in Bi-Tg mice were not explained by consistent changes in TSH, T3 
and T4 levels. Similar to observations in PBF-Tg thyroids,22 microscopic examination of Bi-
Tg thyroids (Figure 1f and Supplementary Figures S2a-e) demonstrated a high occurrence of 
hyperplastic lesions by 78 weeks of age, especially in females (>80% occurrence) compared 
with sex-matched WT (Supplementary Figure S2f; P<0.05). In contrast, PTTG-Tg thyroids in 
aged mice retained normal cellular architecture (Supplementary Figure S2g). Positive 
immunostaining with the proliferation markers cyclin D1 (Supplementary Figure S3) and 
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cyclin A (Supplementary Figure S4) further demonstrated that PBF and PTTG co-expression 
resulted in increased thyroid cell proliferation in vivo.  
Taken together our results show that thyroidal co-expression of PBF and PTTG in vivo 
gives rise to mice phenotypically more similar to PBF-Tg than PTTG-Tg mice, but with 
significant differences in thyroid gland size and overall survival.  
 
Modulation of DDR gene expression by raised PBF and PTTG 
Separate studies have implicated PBF and PTTG in tumourigenesis due to their ability to 
regulate p53 genes involved in DDR, cell-cycle and apoptotic pathways.27,29 Having 
established the Bi-Tg murine model, we next characterised the impact of simultaneous 
induction of these proto-oncogenes on DDR genes in primary thyrocytes. Importantly, 
significant changes in gene expression occurred in Bi-Tg thyrocytes in response to raised 
PTTG and PBF compared to WT (Figure 2a; n=41/82 genes; P<0.05). The majority of genes 
were down-regulated >1.5-fold (Supplementary Figure S5a and Figure 2b and c; n=31), 
including those known to maintain genomic integrity, such as Brca1 (2.9 ± 0.1 fold; P<0.001) 
and Pms2 (2.8 ± 0.1 fold; P<0.01). Overall the DDR transcriptional signature in Bi-Tg 
thyrocytes was distinct compared to either PTTG-Tg or PBF-Tg (Supplementary Figure S5b). 
In particular, there was significant repression for a subset of 41 DDR genes with relative 
expression >0.8 (range 0.8-3.2 in PTTG-Tg) between Bi-Tg and PTTG-Tg thyrocytes (Figure 
2b and Supplementary Figure S5c; P=1.8x10-5). Further experiments confirmed significant 
changes in DDR genes Brca1, Chek1 and Exo1 between genotypes (Figure 2d). Seven genes 
with >1.5-fold reduction were identified solely in Bi-Tg thyrocytes (Figure 2e), of which six 
were p53 target genes (Supplementary Figure S6 and Supplementary Table S1) such as Mgmt 
that has been associated with increased genomic instability in thyroid carcinoma.30  
Western blot analysis indicated that p53 protein levels were elevated in PTTG-Tg 
(2.2±0.5-fold; P<0.05) and Bi-Tg (3.2±0.9-fold; P<0.05) thyroids which might account for 
some transcriptional differences (Figure 2f and g). An intense pattern of pChek1(Ser 345) 
expression in Bi-Tg thyrocytes implicated replication stress as a potential explanation for p53 
activation (Supplementary Figure S7). Interestingly, p53 protein was not altered in PBF-Tg 
thyroids (Figure 2f).  
To examine the influence of p53 further we irradiated thyrocytes to amplify p53 levels in 
response to DNA damage. The most significant overall reduction for DDR genes following 
DNA damage was between irradiated Bi-Tg and WT thyrocytes (P=2.4x10-4) compared with 
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either PBF-Tg (P=1.5x10-3) or PTTG-Tg thyrocytes (P=NS) (Figure 3a-d). Importantly, 
subsequent validation confirmed that DDR genes Chek1, Brca1, Rad51 and Exo1 were most 
highly suppressed in irradiated Bi-Tg thyrocytes (Figure 3e and Supplementary Figure S8). In 
control experiments irradiation did not alter protein expression of PBF and PTTG (Figure 3f). 
Given the extent of suppression of DDR genes, we next used fluorescent inter simple 
sequence repeat (FISSR) PCR to determine whether there was any associated impact on 
genetic instability with PBF and PTTG.16,17 In comparison to primary thyrocytes derived 
from age- and sex-matched WT mice (arbitrarily assigned a GI of 0%), Bi-Tg thyrocytes 
demonstrated the most disrupted genome, with a mean GI index of 35.8±2.6% (Figure 3g; 
P<0.001). This level of GI was significantly greater than in the genomes for PBF-Tg 
(18.8±1.8%; P<0.01) and PTTG-Tg (7.2±1.6%; P<0.001) thyrocytes. To determine whether 
PBF and PTTG might also contribute to gross chromosomal aberrations we next examined 
metaphases of thyroidal TPC-1 cells. Strikingly, co-expression of PBF and PTTG produced 
>6-fold increase in the number of chromatid aberrations compared to PBF-, PTTG- or VO- 
control cells in the absence of irradiation (Figure 3h-i and Supplementary Figure S9a; 
P<0.01). Similarly, chromosomal aberrations in PBF+PTTG-overexpressing TPC-1 cells 
irradiated with a dose of 1 Gy were significantly greater than in all controls (Figure 3j; 
P<0.001). Further studies confirmed that PBF and PTTG suppressed DDR genes in TPC-1 
cells (Supplementary Figure S9b). 
Collectively, these results provide evidence for the ability of PBF and PTTG together to 
drive genomic instability in thyroid cells that may be due to alterations in the regulation of 
DDR genes required for normal replication or impaired p53-dependent signalling. 
 
Elevated PTTG and PBF are associated with DDR genes in DTC 
Whilst PBF and PTTG have been reported individually to be overexpressed in human DTC, 
there is a lack of information regarding their co-expression in tumours. To extend our 
findings to human DTC, we examined PBF and PTTG expression by RNA-seq (TCGA) in 59 
matched thyroid tumour and normal samples.4 We found that PBF and PTTG expression 
were simultaneously up-regulated in 18.6% of DTC cases (Figure 4a; n=11/59), while PBF 
was higher in ~70% of tumours (n=41/59) compared to 24% with positive PTTG expression 
(Figure 4a; n=14/59). The subsequent challenging of our findings in our in-house matched 
FFPE tumour and normal DTC demonstrated a comparable number of tumours (n=6/30; 
20%) with positive PBF and PTTG expression (Figure 4b).  
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Having identified a subset of DTC with elevated PBF and PTTG expression, we 
investigated their relationship with DDR and p53 target genes. DAVID analysis31,32 of 
differentially expressed genes confirmed the involvement of genes in DNA repair and p53 
pathways by comparing DTC with either low or high PBF/PTTG expression (Figure 4c and 
Supplementary Figures S10 and S11). Importantly, DDR genes previously identified in Bi-Tg 
thyrocytes (Figure 2a) were altered significantly between DTC subsets (Figure 4d and 
Supplementary Figure S12; n=18/41 genes). Further evaluation revealed significant 
correlations between DDR genes with PBF (Supplementary Figure S13a; n=13/18 genes) and 
PTTG alone (Supplementary Figure S13b; n=16/18 genes). In addition, there were striking 
correlations with PBF and PTTG in well-characterised DDR and p53 target gene panels 
(>60% of genes; 81-95 genes per panel; P<0.05) using unmatched TCGA samples (Figure 4e 
and Supplementary Figures S14 and S15; n=322). The most significant correlations with PBF 
and PTTG, for instance, were observed in DTC with Cry2, Apex1, Rad50 and Atm (Figure 
4f). A list of differentially expressed genes in DTC with high PBF/PTTG is provided 
(Supplementary Table S2). Altogether these findings demonstrate significant associations 
between PBF and PTTG with DDR and p53 target genes (Supplementary Table S1) in human 
DTC, as well as in the murine Bi-Tg thyroid model. 
 
Association of genetic abnormalities with PBF and PTTG  
Genomic profiling has revealed extensive diversity in mutations and fusion driver genes 
associated with thyroid cancer.4 To gain insights into alterations that might influence PBF 
and PTTG in the genetically diverse tumour environment, we next correlated their expression 
with invasive properties and mutational status in DTC. We found that PBF expression was 
significantly greater in regional metastatic DTC (N1) for matched tumour and normal 
samples in TCGA (Figure 5a; P<0.05) and FFPE thyroid specimens (Supplementary Figure 
S16; P<0.05) than in non-metastatic DTC (N0). Of particular significance, PBF expression 
was higher in BRAF-mutant DTC compared to non-BRAF variants (Figure 5b; P<0.01). 
Similarly, PBF expression was elevated in BRAF-mutant DTC in a larger cohort of 
unmatched TCGA cases (Figure 5c; P<0.001 vs non-BRAF; n=255). These findings 
paralleled our in vitro studies in which BRAFV600E over-expression induced PBF in TPC-1 
cells (Figure 5d). In agreement with this, the addition of the MEK inhibitor selumetinib 
effectively blocked induction of PBF protein by BRAFV600E (Figure 5e). Control experiments 
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confirmed that PBF and PTTG overexpression did not activate MEK/ERK signalling 
(Supplementary Figures S9b and S17a). 
We also observed that higher PBF was associated with the receptor tyrosine kinase (RTK) 
genes NTRK1, NTRK3 and RET (Figure 5f; P<0.001) but remained unchanged for RAS 
genes (Figure 5f; P=NS). In contrast, PTTG expression was lower in both RAS- (Figure 5f; 
P<0.01) and BRAF-mutant DTC (Figure 5g; P<0.001). The relative levels of PTTG however 
tended to be raised in RTK-mutant DTC (Figure 5f), which reached significance for NTRK3 
fusion genes (Figure 5g; P<0.05). In keeping with this, the highest frequency of BRAF-
mutation in DTC (82.8%; n=53/64) corresponded with the top quartile (Q4) of PBF 
expression compared to 48.4% for DTC with the bottom quartile Q1 (Figure 5h; P<0.0001; 
n=31/64). By comparison, DTC with top quartile PTTG expression (Figure 5i) had the lowest 
frequency of BRAF-mutation (44.6% in Q4 vs 81.8% in Q1; P<0.001) and highest frequency 
of RET alterations (19.6% in Q4 v 0% in Q1; P<0.001). Overall, fusion driver genes (FDG) 
were ~2-fold more prevalent in DTC with high PTTG expression (Figure 5i; top quartile; 
34.4%) compared to all 255 cases of DTC (Figure 5j; 17.9%; P<0.01). 
These results demonstrate for the first time that the underlying genetic alteration in DTC is 
related to distinct patterns of PBF and PTTG expression. Furthermore, PBF overexpression 
was associated with regional metastatic DTC. 
 
High expression of PBF and PTTG in DTC is associated with poor patient survival 
To further define the molecular subtypes of DTC associated with high expression of both 
PBF and PTTG, we applied hierarchical clustering to matched tumour/normal DTC data 
using a panel of 13 DDR genes and identified 3 main clusters (Figure 6a; n=59). BRAF 
(n=10/21) and RET (n=3/21) were frequent alterations in cluster 1 (i.e. elevated PBF and 
PTTG), while mutated BRAF was present in all cases of DTC in cluster 3 (Figure 6a; i.e. 
high PBF and low PTTG; n=14/14). The unmatched DTC dataset (n=255) supported these 
observations with BRAF (70%) and RET (25%) the most common alterations in DTC with 
elevated PBF and PTTG (Figure 6b; top quartile; n=25), while BRAF was more prominent in 
DTC (87.5%) with high PBF and low PTTG expression (Figure 6b; n=19). Overall the 
occurrence of fusion driver genes was greatest in DTC with elevated PBF and PTTG (Figure 
6b; 28%), especially the ETV6-NTRK3 rearrangement (n=3/7) which is associated with 
exposure to 131I.33 In contrast, mutated NRAS was more common in DTC with low PBF and 
PTTG expression in matched (Figure 6a; cluster 2; n=4/22) and unmatched (Figure 6b; 
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18.2%; n=28) DTC. Importantly, the expression of DDR genes in unmatched DTC samples 
was also significantly altered (P<0.05) in DTC with high PBF and PTTG (top quartile) 
compared to DTC in other expression subsets (Figure 6c and Supplementary Figures S18 and 
S19), as well as demonstrating unique correlations in a panel of DDR genes (Supplementary 
Figure S20). 
Having observed strong repression of DDR genes in DTC with elevated PBF and PTTG, 
we next evaluated whether this correlated with tumour aggressiveness and patient survival. 
The TCGA clinical dataset showed significantly poorer survival (P=0.003) and disease-free 
survival (P=0.043) for patients (n=25) with high tumoural PBF and PTTG expression than 
for all other patients (Figure 6d; n=255). In particular, poor overall survival was a 
characteristic for patients with BRAF-mutant DTC (P=1.91x10-5) and not non-BRAF mutant 
DTC (Figure 6d and Supplementary Figure S21; P=NS). Further analysis of BRAF-mutant 
DTC alone confirmed these observations and showed that PBF and PTTG status were both 
required to identify aggressive tumours associated with poor patient survival, as well as a 
higher incidence of stage IVA disease (Supplementary Figure S22a and b). Potential high-
risk modifiers (e.g. USP9X) in aggressive BRAF-mutant DTC with elevated PBF and PTTG 
were also identified (Supplementary Figure S22c). By comparison, high tumoural expression 
of a panel of proliferation markers was not associated with diminished overall patient 
survival (Supplementary Figure S23). 
Taken together our study reveals that expression patterns of PBF and PTTG in thyroid 
cancer cells are intimately linked to specific genetic alterations and may promote oncogenic 
characteristics such as modulating the DNA damage response. We therefore propose that 
PBF and PTTG have a critical role in promoting thyroid cancer that correlates with poorer 
patient survival. 
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DISCUSSION 
Differentiated thyroid cancer is the most rapidly increasing cancer in the UK and US, with 
~300,000 new cases reported worldwide annually.34 Extensive genomic profiling has recently 
identified new driver mutations and fusion driver genes in thyroid tumours.4 However, a 
better understanding of contributory factors that promote aggressive tumours is urgently 
needed to reduce the >38,000 worldwide deaths from thyroid cancer per annum.  In separate 
studies we previously implicated elevated expression of the proto-oncogene PTTG and its 
binding partner PBF in thyroid cancer.5,6 Our current findings now demonstrate for the first 
time a role for PBF and PTTG together in modulating genes associated with the DNA 
damage response that is predictive of poor survival in thyroid cancer. 
Disruption of p53 activity has a critical role in promoting tumourigenesis for most human 
cancers. This role is relatively undefined in DTC however due to a very low incidence of p53 
mutations,4 although a recent study detected p53 mutations in 73% of aggressive anaplastic 
thyroid carcinomas (ATC).35 In the present study a comparative approach was used in a novel 
bi-transgenic model and human TCGA data to examine the impact of PBF and PTTG on a 
panel of DDR genes of which the majority were p53 target genes and known to be impaired 
in cancer cells.36 A remarkable finding was that many DDR genes were highly repressed in 
both murine thyrocytes and human thyroid tumours in the presence of raised PBF and PTTG. 
Our findings therefore provide strong evidence of a model in which overexpression of PBF 
and PTTG impairs DDR gene activity thus promoting tumour progression.  
The association between PTTG and DDR pathways has been described in multiple 
studies,14 with DDR genes up-regulated in β-cells in PTTG-null mice,29 as well as in PTTG-
deficient bone marrow stem cells.37 Therefore, our result of extensive repression of DDR 
genes in PTTG-Tg thyrocytes mirrors these earlier observations, and provides support for a 
pivotal role for PTTG in the inhibition of DDR pathways in vivo. Individually, PBF and 
PTTG both regulate p53,27,38 which plays a key role in eliciting many cellular responses to 
DNA damage. Here, we found significant induction of p53 protein in PTTG-Tg and Bi-Tg 
thyroids, which was consistent with greater DDR gene changes and correlated with in vitro 
studies demonstrating p53 induction by PTTG in transformed cell lines38 and human 
fibroblasts.13  
In contrast, the impact of PBF on p53 and DDR pathways is less well understood due to a 
lack of mouse knockout models. Here we demonstrated in murine thyrocytes that DDR genes 
were more highly repressed in the presence of raised PBF and PTTG following irradiation 
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than with either PBF or PTTG alone. In addition, expression of well-characterised panels of 
DDR and p53 target genes were highly correlated with PBF and PTTG levels in human DTC. 
The underlying mechanism might share a common pathway especially as both proto-
oncogenes bind specifically to p53 and block transcriptional activity.25,27,28 PBF however also 
interacts with PTTG18 and the ability of PBF to facilitate the translocation of PTTG to the 
nucleus18 might augment interaction with p53 to repress DDR genes, especially in cells 
stressed by irradiation with increased nuclear p53. In addition, our study and others39 have 
implicated PTTG in promoting replication stress which is associated with activation of p53.40 
The exact mechanism for PBF regulation of p53-responsive DDR genes in combination with 
PTTG is therefore likely to be multifaceted and remains to be fully clarified. In particular, it 
will be important to determine whether PTTG influences the ability of PBF to inhibit p53 
transcriptional activity or diminish p53 stability by enhancing ubiquitination27, as well as 
better defining the contribution of p53-independent pathways on DDR gene modulation. 
Inhibition of DDR genes in the tumour environment contributes to genomic instability and 
promotes cancer progression.41 Given the extent of repression of DDR genes in transgenic 
thyroids, we examined genetic instability which has previously been reported in thyroid 
cancer.16,42,43 An important finding was that genetic instability in Bi-Tg thyrocytes was 
greater than in either PTTG-Tg or PBF-Tg thyrocytes. However, tumour induction was 
absent in Bi-Tg thyroids, despite extensive hyperplasia, repressed DDR genes and elevated 
genetic instability. Previously, a PTTG transgenic mouse was crossbred with a p53(+/-) 
mouse to effectively induce ovarian tumours,44 which infers a contributory role for PTTG. To 
further define the oncogenic roles of PBF and PTTG in the Bi-Tg mouse it will therefore be 
necessary to cross-breed with p53-null mice to model ATC or transgenic mice with DTC 
driver mutations such as BRAFV600E.45  
In this study we aimed to correlate our findings in the Bi-Tg mouse model to human DTC. 
An important consideration was to determine which genetic alterations were associated with 
high PBF and PTTG expression. In particular, genetic drivers in PTC have distinct signalling 
consequences and have been categorised into BRAFV600E-like (BVL) and RAS-like (RL) 
PTCs according to distinct gene signatures.4 In this study high PBF expression was associated 
predominately with alterations that were highly (i.e. BRAF mutations) or weakly BVL (i.e. 
RET fusions), as well as a few potentially neutral BVL (i.e. NTRK1/3 fusions). Critically, 
there was no association with the RL phenotype and RAS mutations. Downstream signalling 
events in BVL-PTCs are therefore likely to be responsible for increased PBF expression, 
especially as the top quartile of PBF expression corresponded with a majority of BRAF 
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(82.8%) and RET (7.8%) alterations. Importantly, we were able to confirm that 
overexpression of BRAFV600E in thyroid cancer cells led to increased PBF protein levels. 
Together our findings reveal a novel role for PBF as an integral downstream target of the 
BRAF signalling pathway to promote thyroid tumourigenesis.  
In contrast, genetic alterations linked to raised PTTG were less clear, especially as high 
PTTG expression was detected in just ~25% of DTC compared to almost 70% for PBF. 
Fusion genes such as ETV6-NTRK3 were associated with high PTTG expression in a small 
subset of DTC. Low PTTG expression was however predominately associated with mutations 
that were highly BVL (i.e. BRAF) and RL (i.e. RAS). Importantly, our cluster and quartile 
expression data analysis showed that BRAF and RET were the main driving events in PTCs 
with high PBF and PTTG expression. It will be important to establish whether this subset of 
DTC has a unique molecular profile or corresponds to one of the four distinct classifications 
of BRAF-mutant PTC.4 In addition, a distinguishing feature was the high prevalence of 
fusion driver genes in DTC with raised PBF and PTTG compared to other DTC expression 
subsets, which most likely reflects an increased number of oncogenic chromosomal 
translocations due to greater disruption of DNA repair processes.46 In support of this, we 
demonstrated significantly greater levels of gross chromosomal aberrations in thyroid TPC-1 
cells by overexpressing PBF and PTTG.  
The immediate challenges in thyroid cancer are to identify new biomarkers and molecular 
targets for small subsets of DTC that are more aggressive and more likely to recur. Here, both 
the overall survival and disease-free survival rates were significantly reduced in a subset of 
DTC with high PBF and PTTG expression. These findings therefore suggest that the status of 
PBF and PTTG should together be regarded as an important clinical indicator for aggressive 
thyroid disease. In particular, diminished patient survival was a characteristic of BRAF-
mutant DTC and not tumours with RET fusion genes. Further evidence linking DDR genes 
and tumour aggressiveness was revealed by a panel of DDR genes identified in murine Bi-Tg 
thyroids, including cancer-associated genes such as Brca1 and Atm, which were also 
significantly repressed in human DTC with raised PBF and PTTG.  
In summary, our study based on comparative analysis of mice and human data 
demonstrates that PBF and PTTG have a pivotal role in modulating DDR genes in thyroid 
cells, as well as altering genomic instability, both characteristics that expedite malignant 
initiation and progression.24,41 Indeed, these results raise the possibility that abrogation of 
DDR genes by PBF and PTTG might also impact on emerging oncogenic roles for DDR 
genes such as spontaneous epithelial to mesenchymal transition observed in BRCA1-depleted 
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cells.47 Further, we have defined the genetic alterations in DTC correlated with PBF and 
PTTG, thereby providing novel insights into the integral role of these proto-oncogenes in 
thyroid cancer pathways. We therefore propose that high tumoural expression of PBF and 
PTTG contributes to significant disruption of DDR regulated activity that is associated with 
poorer clinical outcome.  
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MATERIALS AND METHODS 
Human tissue, cell culture and transfection 
Human thyroid samples were obtained with local ethics committee approval (Birmingham 
Clinical Research Office, UK) and informed patient consent. Thyroid TPC-1 cells were 
kindly provided by Dr Rebecca Schweppe (University of Colorado, Denver, CO, USA) and 
maintained in RPMI 1640 (Life Technologies, Paisley, UK) supplemented with 10% fetal 
bovine serum, penicillin (105 U/l), and streptomycin (100 mg/l). Cells were cultured as 
recommended at low passage and authenticated by short tandem repeat analysis (DNA 
Diagnostics Centre, London, UK) and tested for mycoplasma contamination (EZ-PCR kit; 
Geneflow, Lichfield, UK). pEFP BRAFV600E containing BRAFV600E cDNA was kindly 
provided by Jim Fagin (Memorial Sloan-Kettering Cancer Center, New York, USA). Cells 
were transfected using TransIT LT1 (Mirus Bio LLC, Madison, WI, USA) according to 
manufacturer's protocol.  
 
Transgenic mice and primary thyrocytes 
Wild-type (WT) and transgenic FVB/N mice were bred at the Transgenic Mouse Facility 
(University of Birmingham, UK) and all experiments performed in accordance with U.K. 
Home Office regulations. Generation of PTTG-Tg and PBF-Tg transgenic mice have been 
described previously.22,48 The bitransgenic line (Bi-Tg) was generated by crossbreeding PBF-
Tg and PTTG-Tg mice. Mice were genotyped using tail DNA and PCR protocols as 
described.22 Equivalent numbers of male and female mice were used per group unless 
otherwise stated. Power calculations (biomath.info/power/ttest.htm) showed that at least 6 
mice were sufficient to detect a 30% change in thyroid size (power=0.8, alpha=0.05). No 
blinding or randomisation of mice allocation was performed. Thyroid glands were removed 
and primary thyrocytes cultured as described previously.27 Seven days after seeding DNA 
damage was induced by Caesium-137 irradiation at 20 Gy dose (IBL 437C type H unit, CIS 
Bio international, Gif-Sur-Yvette, France).  
 
RNA analysis 
Total RNA was extracted using the RNeasy Micro Kit (Qiagen, Manchester, UK) prior to 
reverse transcription using the Reverse Transcription System (Promega, Madison, USA). 
Expression of specific mRNAs was determined on a 7500 Real-time PCR system (Applied 
Biosystems) using primers listed in Supplementary Table S3. Total RNA was extracted from 
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human thyroids using the RNeasy FFPE kit (Qiagen) as per manufacturer’s instructions and 
expression determined using the QuantiTect Probe RT-PCR kit (Qiagen). Relative expression 
was calculated using the 2-∆∆Ct method. Gene expression was also analysed using the DNA 
damage signalling pathway-focused RT2 Profiler PCR Array (Qiagen) according to 
manufacturer’s instructions.  
 
Thyroid function  
Total T3 and total T4 in the serum of WT and transgenic mice were measured after 
centrifugation of clotted blood samples using RIA kits (MP Biomedicals, Solon, OH, USA). 
Mouse serum concentrations were determined by Prof Samuel Refetoff (University of 
Chicago, Chicago, IL, USA).  
 
Western blotting and Immunohistochemistry 
Western blot and immunohistochemical analyses were performed as described previously.20,49  
Primary antibodies against PBF (custom20,49), HA (MMS-101P; BioLegend, San Diego, CA, 
USA), hPTTG (700791; Invitrogen, Paisley, UK), phospho-p44/42 MAPK (Erk1/2) (9101), 
p44/42 MAPK (Erk1/2) (4695), Myc-Tag (2276; Cell Signaling Technology, Danvars, MA, 
USA),  p53 (sc-126; Santa Cruz Biotechnology, Dallas, TX, USA), cyclin D1 (ab16663), 
cyclin A2 (ab181591; Abcam, Cambridge, UK), Chk1 (GTX50463), Brca1 (GTX50557; 
GeneTex, Irvine, CA, USA), phospho-CHK1(Ser345) (PA5-34625; Thermofisher Scientific, 
Waltham, MA, USA) and β-actin (A5441; Sigma-Aldrich, Dorset, UK) were used. 
Densitometry was performed on blots scanned into Photoshop (Adobe Systems) and analysed 
using ImageJ as described.27 
 
Analysis of genomic instability 
Fluorescent inter simple sequence repeat (FISSR)-PCR amplications were performed as 
described previously17,27 using a 5’-6-carboxyfluorescein-labeled primer (CA)8RG with 5 ng 
genomic DNA. PCR products were electrophoresed on an ABI3730 capillary sequencer 
(Applied Biosystems, Foster City, CA, USA), and data analysed using Peak Scanner 
software. Five replicate experiments were performed to verify the reproducibility of the 
assay. The degree of genetic instability was determined as described50 to generate the GI 
index, which represents the standard measure of GI with ISSR-PCR analysis. Chromosomal 
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aberrations were scored in Giemsa stained metaphase spreads as described previously51 
(Supplementary Methods). 
 
Datasets 
Normalized gene expression data generated using the Illuminia RNA-seq platform and 
clinical information was downloaded from cBioPortal.52,53 Gene expression values were 
transformed as X=log2(X+1) where X represents the normalized fragments per kilobase 
transcript per million mapped reads (FPKM) values. For matched normal (N) and tumour (C) 
pairs relative fold-changes (FC) were transformed as log2FC = log2(C) – log2(N) where C and 
N represent normalized FPKM values. Transcriptome datasets were selected for tumours with 
TNM staging of T1-3N0 (non-metastatic) or T1-3N1 (lymph node metastasis). In total 
RNAseq data for 322 unmatched DTC and 59 matched DTC/normal samples were used. 
Non-parametric Mann-Whitney, Kruskal-Wallis and Spearman’s correlation tests were 
performed as expression levels of PBF and PTTG in TCGA datasets were not normally 
distributed. 
 
Statistical analysis 
All results were obtained from triplicate experiments unless otherwise indicated. Data were 
analysed using IBM SPSS Statistics (version 22) and Microsoft Excel. The biological number 
of samples and corresponding statistical test and significance level is indicated in each figure 
legend. Normal distribution and homogeneity of variance has been tested using the 
D’Agostino-Pearson test of normality and the F-test. P<0.05 were considered significant. 
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FIGURE LEGENDS 
Figure 1. Enlargement of thyroid glands in Bi-Tg mice. (a) Schematic of the bovine Tg-
PTTG-FLAG and Tg-PBF-HA transgenes. (b) Detection of PBF and PTTG expression by 
Western blot analysis of WT and transgenic thyroids. (c) Thyroid weight of WT and 
transgenic mice (mean±s.d., number (n) and mean age (d) of mice are indicated, unpaired 
two-tailed t-test) (NS, not significant; ***P<0.001). (d) Thyroid: body weight ratios of male 
(M) and female (F) transgenic mice at 7 weeks of age (mean±s.d., number (n) of mice are 
indicated, unpaired two-tailed t-test) (NS, not significant; **P<0.01; ***P<0.001). (e) 
Kaplan-Meier survival curves for WT (n=30), PTTG-Tg (n=129), PBF-Tg (n=82) and Bi-Tg 
(n=89) mice. P-values were determined using the log-rank test (*P<0.05). (f) Representative 
H&E stained images of hyperplastic lesions in Bi-Tg thyroids from 78-week old mice. WT 
thyroid follicles (right) are shown for comparison. Scale bar, 100 µm. 
 
Figure 2. Impaired DDR gene expression in Bi-Tg thyroids. (a) Pie chart summarizes 
number of DDR gene expression changes between thyrocytes from male Bi-Tg and WT mice 
(n=3 arrays). Graph (below) shows DDR genes with mRNA repressed ≥2.0-fold in Bi-Tg 
thyrocytes (mean, n=3, unpaired two-tailed t-test) (*P<0.05; **P<0.01; ***P<0.001). (b) 
Transcriptional signature of subset of DDR genes in PTTG-Tg (triangles), PBF-Tg 
(diamonds) and Bi-Tg (squares) thyrocytes with relative expression >0.8 (range 0.8-3.2 in 
PTTG-Tg) (mean, n=3 arrays, 1Kruskal-Wallis test, 2Mann-Whitney test) (NS, not 
significant; *P=0.018; **P=0.002; ***P=1.8x10-5). Red filled circle indicates p53 target 
gene. SRD5A2, TNP1 and RBBP4 from (a) were not included due to lack of expression in all 
4 genotypes. (c) Same as (b) except using subset of DDR genes with relative expression <0.8 
(range 0.15-0.8 in PTTG-Tg) (*P=0.017; ***P values are shown). (d) qPCR analysis of 
Chek1, Exo1 and Brca1 expression in thyrocytes of indicated genotypes (mean±s.e.m., n=4, 
unpaired two-tailed t-test) (NS, not significant; *P<0.05; **P<0.01; ***P<0.001). (e) Venn 
diagram of DDR genes with repressed expression (>1.5-fold; *P<0.05) for thyrocytes of 
indicated genotype compared to WT (n=3). Genes listed are unique to Bi-Tg thyrocytes 
(box). (f) Western blot of p53 levels in thyroid gland lysates for each genotype as indicated. 
Blot shown is representative from 4 independent experiments. (g) Quantification of mean p53 
protein levels relative to β-actin (mean±s.e.m., n=4, unpaired two-tailed t-test) (NS, not 
significant; *P<0.05). 
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Figure 3. Transcriptional signature of DDR genes in irradiated murine thyrocytes. (a) DDR 
gene expression profile of irradiated (+IR) Bi-Tg and WT thyrocytes (mean, n=3 arrays, 
Mann-Whitney test, ***P=2.4x10-4). (b) Same as (a) except DDR expression profile shown 
between irradiated PBF-Tg and WT thyrocytes. (c) Same as (a) except DDR expression 
profile shown between irradiated PTTG-Tg and WT thyrocytes. (d) Heatmap showing 
relative expression levels for 10 DDR genes between indicated genotypes. (e) Relative fold 
change in Brca1 expression in irradiated (+IR) thyrocytes of each genotype versus non-
irradiated (-IR) controls (mean±s.e.m., n=4, unpaired two-tailed t-test) (NS, not significant; 
*P<0.05; **P<0.01; ***P<0.001). (f) Representative Western blot of PTTG and PBF in 
irradiated (+IR) thyrocytes of each genotype relative to untreated controls (-IR). (g) 
Quantification of genetic instability (GI) in murine primary thyrocytes for each genotype 
(mean±s.e.m., n=5, unpaired two-tailed t-test) (**P<0.01; ***P<0.001). (h) Chromosomal 
aberrations in TPC-1 cells at 48 h post-transfection (VO, n=69; PBF, n=56; PTTG, n=52; 
PBF+PTTG, n=93; Fisher’s exact test). Representative images of PBF+PTTG-induced 
chromatid gaps are shown (right, black arrowheads) (i) Representative metaphase spread of 
TPC-1 cells transfected with PBF+PTTG. Boxed area is magnified showing chromatid break 
(black arrowhead). (j) Chromatid aberrations in TPC-1 cells irradiated with 1 Gy dose at 48 h 
post-transfection (mean±s.e.m., VO, n=32; PBF, n=34; PTTG, n=31; PBF+PTTG, n=47; 
unpaired two-tailed t-test) (NS, not significant; ***P<0.001). Representative metaphase 
spreads for irradiated TPC-1 cells transfected with PBF+PTTG or VO are shown. Boxed 
areas are magnified and show representative chromatid aberrations (i.e. gaps, exchanges and 
breaks respectively). Black arrowheads indicate chromatid aberrations.  
 
Figure 4. Significant association between PBF and PTTG with DDR genes. (a) Scatterplot 
showing fold-change (FC) in PBF and PTTG expression in DTC versus matched normal 
samples (log2, n=59, TCGA dataset). (b) Same as (a) except PBF and PTTG expression in 
matched DTC and normal samples from FFPE tissue (log2, n=30). Shaded areas in (a) and (b) 
indicate DTC with high PBF/PTTG expression. (c) DAVID analysis of differentially 
expressed genes in matched DTC and normal samples with low (n=15) versus high (n=11) 
PBF/PTTG-expressing tumours. P<0.05 for all subgroups (modified Fisher’s exact test). (d) 
Fold-change (FC) in expression of DDR genes repressed in DTC with high PBF/PTTG 
(n=11) versus DTC with low PBF/PTTG (n=15) (mean log2FC±s.e.m., Mann-Whitney test) 
(*P<0.05; **P<0.01; ***P<0.001; see Supplementary Figure S12 for additional data). (e) 
Correlation values (ρ) for PBF (top) and PTTG (bottom) in a panel of DDR genes (n=82) 
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using thyroid TCGA RNA-seq data (n=322). P and ρ values were calculated using 
Spearman’s correlation tests. (f) Correlation of PBF and PTTG expression with indicated 
DDR genes in human thyroid cancer TCGA dataset (n=322, Spearman’s correlation test).  
 
Figure 5. Genetic alterations associated with PBF and PTTG. (a) Fold-change (FC) in PBF 
and PTTG expression in metastatic (N1) and non-metastatic (N0) DTC relative to matched 
normal tissue (N) (mean±s.e.m., N0, n=23; N1, n=21; Mann-Whitney test) (NS, not 
significant; *P<0.05). (b) Fold-change in PBF and PTTG expression in Braf-mutant and non-
Braf mutant DTC relative to matched normal tissue (mean±s.e.m., non-Braf, n=21; Braf, 
n=32; Mann-Whitney test) (NS, not significant; **P<0.01). (c) Box-whisper plots of PBF 
expression (log2) in unmatched DTC with the indicated genetic alteration and number of 
samples (below) (NS, not significant; *P<0.05; **P<0.01; ***P<0.001; Mann-Whitney test). 
(d) Western blot analysis of PBF and BRAFV600E in TPC-1 cells transfected with either VO 
or BRAFV600E. (e) Western blot analysis of PBF, BRAFV600E, pERK1/2, and ERK1/2 in TPC-
1 cells transfected with either VO or BRAFV600E and then incubated with 200 nM 
selumetinib. (f) Expression of PBF (top) and PTTG (bottom) in unmatched DTC with the 
indicated subgroup of genetic alteration (Normal, n=59; Ras, n=25; Rtk, n=33; Mann-
Whitney test) (NS, not significant; **P<0.01; ***P<0.001). (g) Same as (c) but instead 
showing PTTG expression in unmatched DTC samples. (h) Frequency (%) of indicated 
genetic alterations in unmatched DTC with different quartiles (Q1-Q4) of PBF expression. 
Frequency of fusion driver genes (FDG) in each quartile is shown (below) (Q1, Q2 and Q4, 
n=64; Q3, n=63). P-values were determined by Fisher’s exact test. (i) Same as (h) but instead 
showing mutation frequency (%) present in DTC with different quartiles of PTTG 
expression. (j) Frequency of mutations and FDG in all 255 unmatched DTC cases. 
 
Figure 6. Poor patient survival with high PBF/PTTG-expressing tumours and mutant BRAF. 
(a) Hierarchical cluster analysis of matched DTC and normal samples (n=59) based on 
expression of PBF and PTTG, as well as a panel of 13 DDR genes. Significance of 
correlation between DDR genes with PBF (left asterisk) and PTTG (right asterisk) are shown 
(NS, not significant; *P<0.05; **P<0.01; ***P<0.001; Spearman’s correlation test). (b) 
Frequency (%) of genetic alterations in unmatched DTC with different subsets of PBF and 
PTTG expression. Number of DTC samples and frequency of fusion driver genes (FDG) per 
subset are shown. Pie chart (below) summarizes the proportion of FDG in DTC with high 
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PBF/PTTG expression. (c) Reduced expression of a panel of DDR genes in DTC with high 
PBF/PTTG expression. P-values were determined by the Kruskal-Wallis test (median, 
PBF/PTTG expression subsets: low/low, n=28; high/low, n=19; high/high, n=25). Example 
box-whisper plots for PBF, PTTG, ATM and BRCA1 in expression subsets are shown (right) 
(**P<0.01; ***P<0.001; see Supplementary Figures S18-S20 for additional data). (d) TCGA 
clinical data showing overall survival (upper) and disease-free survival (lower) curves for 
DTC of PBF and PTTG expression subsets compared to all DTC cases (n=255). Overall 
survival curves for BRAF-mutant and non-BRAF mutant DTC with high PBF/PTTG 
expression are shown (right) (Number (n) of DTC samples per subset are indicated, P-values 
were determined using the log-rank test). 
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SUPPLEMENTARY INFORMATION 
 
 
 
Supplementary Methods 
Analysis of chromatid aberrations 
Thyroid TPC-1 cells were exposed to 1 Gy dose (IBL 437C type H unit, CIS Bio 
international, Gif-Sur-Yvette, France) and allowed to repair for 1 h at 37ºC prior to addition 
of colcemid (0.2 µg/ml; Thermofisher Scientific, Waltham, MA, USA) for 1 h. Cells were 
trypsinised, treated in hypotonic solution (10.7 mM KCl, 14.3% (v/v) foetal calf serum) for 
20 min at 37 ºC and fixed 3 times in fixative buffer (75% ethanol, 25% glacial acetic acid). 
Fixed cells were dropped onto clean microscope slides and stained with 5% Giemsa stain, 
modified (Sigma-Aldrich, Dorset, UK). Metaphases were viewed under a Zeiss Axioscop 
light-microscope at 100x magnification (Zeiss, Jena, Germany) and images captured using 
Axiovision software. Scoring was performed for the presence of chromatid breaks, gaps and 
exchanges on at least 50 (non-irradiated cells) or 30 (irradiated cells) metaphases per 
experimental condition. All experiments were conducted at least twice. 
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Supplementary Figure S1
Supplementary Figure S1. Characterisation of Bi-Tg mice. (a) Western blot analysis demonstrating PBF and PTTG
expression in thyroid glands harvested from Bi-Tg mice. No significant expression of HA-tagged PBF protein or
FLAG-tagged PTTG was detected in other major organs, including lung, kidney, spleen and liver. Wild-type (WT)
mice were used as controls. (b) Body weight (g) of male (WT, n=14; PTTG-Tg, n=18; PBF-Tg, n=18; Bi-Tg, n=13)
and female (WT, n=18; PTTG-Tg, n=18; PBF-Tg, n=18; Bi-Tg, n=12) mice at 6 weeks of age (mean±s.e.m.,
unpaired two-tailed t-test) (NS, not significant; *P<0.01). (c) Serum TSH concentrations (ng/ml) in male and female
transgenic mice (mean±s.e.m., n=6, unpaired two-tailed t-test) (NS, not significant; *P<0.01). Mouse serum
concentrations were determined by Prof Samuel Refetoff (University of Chicago, Chicago, IL, USA). (d) Serum T3
concentrations (ng/dl) in 6 week old male (WT, n=16; PTTG-Tg, n=6; PBF-Tg, n=15; Bi-Tg, n=6) and female (WT,
n=15; PTTG-Tg, n=6; PBF-Tg, n=12; Bi-Tg, n=6) transgenic mice (mean±s.e.m., unpaired two-tailed t-test) (NS, not
significant; *P<0.01; **P<0.01; ***P<0.001). (e) Serum T4 concentrations (g/dl) in 6 week old male (WT, n=14;
PTTG-Tg, n=6; PBF-Tg, n=6; Bi-Tg, n=6) and female (WT, n=15; PTTG-Tg, n=5; PBF-Tg, n=5; Bi-Tg, n=5)
transgenic mice (mean±s.e.m., unpaired two-tailed t-test) (NS, not significant; *P<0.01; ***P<0.001).
Supplementary Figure S2
Supplementary Figure S2. Thyroid hyperplasia in Bi-Tg mice. (a-e) Representative H&E stained images showing
hyperplastic lesions (arrows, a-c) and a macrofollicular lesion (d) in thyroids harvested from 78-week old Bi-Tg mice
compared to normal follicles in WT thyroid (e). Enlarged nuclei indicative of proliferating or invading cells were
present in hyperplastic lesions (black arrowheads, magnified image in c). (f) Occurrence of hyperplastic lesions in at
least 10 independent sectional planes per Bi-Tg or WT thyroid (n=3-12 per genotype as indicated) (NS , not
significant; *P<0.05; Fisher's exact test). (g) Composite image of an entire thyroid lobe from a 78-week-old WT
(left) and PTTG-Tg (right) mouse. Scale bars, 100 m.
Supplementary Figure S3
Supplementary Figure S3. Cellular proliferation in Bi-Tg thyroids and human thyroid cancer. (a)
Representative images of cyclin D1 expression in wild-type (WT) and Bi-Tg thyroids in 26 week old mice. (b)
Representative images of cyclin D1 expression in a human differentiated thyroid tumour (right panel) and normal
thyroid tissue (left panel). Middle panel shows cyclin D1 expression in malignant cells (black arrowhead)
adjacent to normal thyrocytes (white arrowhead). Scale bars, 100 m.
Supplementary Figure S4
Supplementary Figure S4. Expression levels of cyclin A in thyroid tissue. (a) Representative images of
cyclin A expression in wild-type (WT) and Bi-Tg thyroids in 26 (upper) and 78 (lower) week old mice. (b)
Representative images of cyclin A expression in a human differentiated thyroid tumour (middle and right
panels) and normal thyroid tissue (left panel). Black arrowheads indicate intense nuclear expression of cyclin
A. Scale bars, 100 m.
Supplementary Figure S5. A distinct transcriptional signature for DDR genes in Bi-Tg thyrocytes. (a) DDR genes
down-regulated >1.5-fold (i.e. relative expression level ≤0.66) in Bi-Tg, PTTG-Tg and PBF-Tg thyrocytes vs WT
controls as indicated (mean, n=3 arrays, unpaired two-tailed t-test, P<0.05). (b) Transcriptional signature of 79 DDR
genes in PTTG-Tg (triangles), PBF-Tg (diamonds) and Bi-Tg (squares) thyrocytes (mean, n=3 arrays, 1Kruskal-
Wallis test, 2Mann-Whitney test) (NS, not significant; *P=0.024; ***P-values are shown). Red filled circle indicates
a p53 target gene. Key features of transcriptional signature for Bi-Tg thyrocytes include: (1) significant repression of
a subset of 41 DDR genes between Bi-Tg and PTTG-Tg with expression >0.8 (range 0.8-3.2 in PTTG-Tg;
***P=1.8x10-5); (2) DDR genes repressed in Bi-Tg thyrocytes vs PBF-Tg and PTTG-Tg thyrocytes, including
PMS1, GTF2H1, GADD45, MLH1, MGMT, GTF2H2, POLH, REV1, PARP2, DCLRE1A, PARP1, RAD51C,
XRCC6, TERF1 and UNG; (3) significant down-regulation of DDR genes >1.5-fold (n=31 genes; *P<0.05) in Bi-
Tg vs WT, and (4) significant repression of a subset of 38 DDR genes between Bi-Tg and PBF-Tg thyrocytes with
expression <0.8 (range 0.15-0.8 in PTTG-Tg; ***P=9.42x10-7). SRD5A2, TNP1 and RBBP4 not included from
Figure 2a due to lack of expression in all 4 genotypes. (c) Order of DDR genes plotted in Figure 2b and c are shown.
Supplementary Figure Legends
Supplementary Figure S6. Correlation of DDR transcriptional signature with p53 target gene status. (a)
Transcriptional signature of subset of DDR genes in PTTG-Tg (triangles), PBF-Tg (diamonds) and Bi-Tg (squares)
thyrocytes with relative expression >0.8 (range 0.8-3.2 in PTTG-Tg) (mean, n=3 arrays, 1Kruskal-Wallis test,
2Mann-Whitney test, 3unpaired two-tailed t-test) (NS, not significant; *P=0.018; **P=0.002; ***P=1.8x10-5). Filled
circles (underneath) indicate the status of each DDR gene as a p53 target gene. p53 target gene categories include
DDR genes regulated by a p53 response element (red), the p53-p21 pathway (orange), the p53-miRNA pathway
(blue) and other pathways such as the p53-lincRNA-21 pathway and known interactions with transcription factors
(black). Further information and literature evidence for p53 target gene categories is provided in Supplementary
Table S1. (b) Same as (a) except but using subset of DDR genes with relative expression <0.8 (range 0.15-0.8 in
PTTG-Tg) (*P=0.017; ***P-values are shown). DDR genes with relative expression <0.8 in PTTG-Tg were more
likely to regulated by the p53-miR-34 pathway (10/38 genes) than DDR genes in PTTG-Tg with expression >0.8
(2/41 genes; P=0.011; Fishers exact test). Expression cut-off value of 0.8 was chosen as it approximates to the mean
expression value for all 79 DDR genes in the three transgene genotypes (i.e. 0.82±0.04). SRD5A2, TNP1 and
RBBP4 not included from Figure 2a due to lack of expression in all 4 genotypes. (c) Order of DDR genes plotted in
panels (a) and (b) above.
Supplementary Figure S7. Expression levels of pChek1(Ser345) in thyroid tissue. Representative images of
pChek1(Ser345) expression in wild-type (WT) and Bi-Tg thyroids in (a) 26 and (b) 78 week old mice. (c)
Representative images of pChek1(Ser345) expression in a human differentiated thyroid tumour (middle and right
panels) and normal thyroid tissue (left panel). Scale bars, 100 m.
Supplementary Figure S5
Supplementary Figure S6
Supplementary Figure S7
Supplementary Figure S8
Supplementary Figure S8. Effect of genotype and irradiation on DDR gene expression in
primary thyrocytes. (a) Relative fold changes in Chek1, Rad51 and Exo1 expression in
irradiated (+IR) thyrocytes of each genotype (WT, PBF-Tg, PTTG-Tg and Bi-Tg) versus non-
irradiated (-IR) controls. (mean±s.e.m., n=4, unpaired two-tailed t-test) (NS, not significant;
*P<0.05; **P<0.01; ***P<0.001). (b) Western blot analysis of Brca1 and Chek1 in WT and
Bi-Tg primary thyrocytes either non-irradiated (-) or irradiated (+). Blot shown is
representative from at least 3 independent experiments.
Supplementary Figure S9
Supplementary Figure S9. Chromosomal aberrations and DDR gene expression in TPC-1 cells. (a) Representative
metaphase spreads of TPC-1 cells transfected with VO, PBF or PTTG for 48 h prior to analysis. (b) Relative fold
changes in Rad51, Brca1 and Chek1 expression in TPC-1 cells transfected with either VO or PBF + PTTG and then
incubated with 200 nM selumetinib (mean±s.e.m., n=3, unpaired two-tailed t-test) (NS, not significant; *P<0.05;
**P<0.01).
Supplementary Figure S10
Supplementary Figure S10. Differentially expressed genes in human DTC with low vs high PBF/PTTG expression.
(a) Scatterplot showing fold-change (FC) in PBF and PTTG expression in DTC vs matched normal samples (log2,
n=59, TCGA dataset). Shaded areas indicate DTC samples with low (yellow) and high (blue) PBF/PTTG expression.
(b) Panther (upper) and Reactome (lower) analysis using DAVID to identify p53 pathway and DNA repair genes
differentially expressed in low vs high PBF/PTTG-expressing thyroid tumours. Gene categories and their respective P-
values are indicated (modified Fisher’s exact test). Several genes (underlined) identified by DAVID were previously
found to be significantly repressed in murine Bi-Tg thyrocytes (Figure 2a and Supplementary Figure S5a).
Supplementary Figure S11
Supplementary Figure S11. Enrichment of p53 pathway genes identified by DAVID analysis is specific to DTC
with elevated expression of PBF and PTTG. (a) DAVID analysis of differentially expressed genes in the
unmatched TCGA dataset comparing DTC samples with high PBF/high PTTG tumoural expression (n=25) and
low PBF/low PTTG tumoural expression (n=28). Gene categories enriched for p53 pathway genes are highlighted
in red. P<0.05 for all subgroups (modified Fisher’s exact test). (b) Same as (a) but comparing DTC samples with
high PBF/low PTTG tumoural expression (n=19) and low PBF/low PTTG tumoural expression (n=28). (c) Same
as (a) but comparing DTC samples with low PBF/high PTTG tumoural expression (n=7) and low PBF/low PTTG
tumoural expression (n=28).
Supplementary Figure S12
Supplementary Figure S12. Modulation of DDR genes in DTC with different subsets of PBF and PTTG expression.
Fold-change in expression for a panel of 18 DDR genes is shown using matched thyroid tumour and normal samples
with low PBF/low PTTG (n=15, yellow), high PBF/low PTTG (n=30, green) and high PBF/high PTTG (n=11, blue)
expression (mean log2FC±s.e.m., Kruskal-Wallis test) (NS, not significant; *P<0.05; **P<0.01; ***P<0.001). Gene
expression data for DTC samples with low PBF/high PTTG was not shown due to insufficient samples. The relative
fold-change in expression for DTC samples with high PBF/high PTTG was significantly greater than the subset with
high PBF/low PTTG for 8 DDR genes (i.e. SMC3, PRKDC, WRN, SMC1A, MPG, MGMT, APEX1, TREX1;
P<0.05; Mann-Whitney test; 1-tailed).
Supplementary Figure S13
Supplementary Figure S13. Correlation of DDR genes with PBF and PTTG expression in human DTC. (a-b)
Correlation of PBF (a) and PTTG (b) expression with 18 DDR genes in matched DTC/normal samples (n=59).
P and  values were calculated using Spearman’s correlation tests. Representative scatterplots showing
significant correlations for fold-change (FC) in Apex1, Cry2, Wrn and Mgmt expression with either PBF (a) or
PTTG (b) are shown on right.
Supplementary Figure S14
Supplementary Figure S14. Correlation of PBF expression in DDR and p53 target gene panels. (a) Heatmap showing
relative correlation values () for PBF expression with a panel (#1) of 82 DDR genes using TCGA data (n=322
unmatched DTC samples). Significant correlations (*P<0.05) were observed with PBF for ~60% of DDR genes
(n=49/82 genes). P and  values were calculated using the Spearman’s correlation test. (b) Heatmap showing relative
correlation values () for PBF expression with a panel (#2) of 95 p53 target genes using TCGA data (n=322 unmatched
DTC samples). Significant correlations (*P<0.05) were observed with PBF for 62% of p53 target genes (n=59/95
genes; Spearman’s correlation test). (c) Representative scatterplots showing significant correlations for expression of
BCL2, BID and CCND1 with PBF (n=322; Spearman’s correlation test). Further information on gene panel #1 and #2
is provided in Supplementary Table S1.
Supplementary Figure S15
Supplementary Figure S15. Correlation of PTTG expression in DDR and p53 target gene panels. (a) Heatmap
showing relative correlation values () for PTTG expression with a panel (#1) of 81 DDR genes using TCGA data
(n=322 unmatched DTC samples). Significant correlations (*P<0.05) with PTTG were observed for 70.4% of DDR
genes (n=57/81 genes). P and  values were calculated using the Spearman’s correlation test. (b) Representative
scatterplots showing significant correlations for expression of MSH2, PRKDC and MIF with PTTG (n=322;
Spearman’s correlation test). (c) Heatmap showing relative correlation values () for PTTG expression with a panel
(#2) of 95 p53 target genes using TCGA data (n=322 unmatched DTC samples). Significant correlations (*P<0.05)
with PTTG were observed for 75.8% of p53 target genes (n=72/95 genes; Spearman’s correlation test). Further
information on gene panel #1 and #2 is provided in Supplementary Table S1.
Supplementary Figure S16
Supplementary Figure S16. Association of metastatic DTC with increased PBF expression. (a)
Representative H&E stained images of matched FFPE DTC (C) and normal (N) thyroid tissue.
Boxed areas represent boundaries of tissue used for RNA extraction. (b) Quantification of relative
PBF (N0, n=27; N1, n=7) and PTTG (N0, n=23; N1, n=6) mRNA expression in metastatic DTC
(N1) and non-metastatic DTC (N0) relative to matched normal tissue (mean±s.e.m., two-tailed
Mann-Whitney test) (NS, not significant; *P<0.05).
Supplementary Figure S17
Supplementary Figure S17. Expression of pERK1/2 in thyroid tissue. (a) Representative images of pERK1/2
expression in wild-type (WT) and Bi-Tg thyroids in 26 week old mice. (b) Representative images of pERK1/2
expression in a human differentiated thyroid tumour (middle and right panels) and normal thyroid tissue (left
panel). Scale bars, 100 m.
Supplementary Figure S18
Supplementary Figure S18. Repressed DDR gene activity in DTC with high PBF/PTTG
expression. Box-whisper plots showing relative expression of 10 DDR genes in unmatched DTC
with different subsets of PBF and PTTG expression. P-values were determined by the Mann-
Whitney test (median, PBF/PTTG expression groups: low/low, n=28; high/low, n=19; high/high,
n=25) (*P<0.05; **P<0.01; ***P<0.001). DTC samples with low PBF/high PTTG expression
were not used due to insufficient numbers for meaningful and comparative analysis. Non-parametric
analysis of DTC samples comparing the 3 subsets of PBF/PTTG expression also showed a
significant difference for all 10 DDR genes (**P<0.01, Kruskal-Wallis test, analysis not shown).
Supplementary Figure S19
Supplementary Figure S19. DDR gene expression in unmatched DTC samples with different PBF/PTTG populations.
(a) Graph summarises the number of DDR genes in panel #1 with expression levels significantly different in DTC with
high PBF/high PTTG tumoural expression (n=25) compared to the other three DTC populations [(i.e. low PBF/low
PTTG (n=28), low PBF/high PTTG (n=7) and high PBF/low PTTG (n=19)]. Expression of 15 DDR genes in DTC
with high PBF/high PTTG expression were significantly different than in the 3 other DTC populations as indicated. Of
these 15 DDR genes, 11 were identified as p53 target genes and are highlighted in yellow (see Supplementary Table
S1) (**P<0.05, Mann-Whitney test; 1-tailed). (b-c) Example box-whisper plots for the indicated genes (i.e. MPG,
UBE2A, TLK1, GTF2H1, REV1, CRY2, SMC1A, MLH3, DCLRE1A and RAD50) in DTC with different PBF/PTTG
expression subsets as indicated (**P<0.01; ***P<0.001; Kruskal-Wallis test).
Supplementary Figure S20
Supplementary Figure S20. Correlation of DDR genes in unmatched DTC samples with different PBF/PTTG
populations. (a) Correlation of PBF expression with 18 DDR genes in unmatched DTC with both high PBF/high PTTG
(n=25) and low PBF/low PTTG expression (n=28; 53 DTC samples in total). P and  values were calculated using
Spearman’s correlation tests; *P<0.05. Correlations were further determined in DTC with both high PBF/low PTTG
and low PBF/low PTTG expression (middle panel; n=19; 47 DTC samples in total), as well as in DTC with both low
PBF/high PTTG and low PBF/low PTTG expression (right panel; n=7; 35 DTC samples in total). (b) Same as (a) but
correlation of PTTG expression was determined for 18 DDR genes in DTC samples. The majority of correlations were
unique to DTC with high PBF/high PTTG expression (i.e. 11/16 genes for PBF and 14/17 genes for PTTG). Although
in a few cases overexpression of one proto-oncogene appeared responsible for the correlation. There was significant
correlation of PTTG, for instance, with three genes (MGMT, SMC3 and TREX1) in the low PBF/high PTTG
population as well as in the high PBF/high PTTG population. In addition, there was a significant correlation of PBF
with five genes (BRCA1, CRY2, DCLRE1A, MLH3 and TREX1) in the high PBF/low PTTG population as well as in
the high PBF/high PTTG population.
Supplementary Figure S21
Supplementary Figure S21. PBF and PTTG expression with BRAF status is predictive of clinical outcome. (a)
TCGA clinical data showing overall survival (upper) and disease-free survival (lower) curves for DTC with high PBF
and PTTG expression (n=25) compared to all DTC cases (n=255). P-values were determined using the log-rank test.
(b) Disease-free survival curves for BRAF-mutant (n=14) and non-BRAF mutant DTC (n=11) with high PBF and
PTTG expression. P-values were determined using the log-rank test. (c) Pie charts summarize the neoplasm disease
stage and overall survival status of DTC with high PBF and PTTG expression and either mutant BRAF (upper) or non-
mutant BRAF (lower).
Supplementary Figure S22
Supplementary Figure S22. Reduction in patient survival with BRAF-mutant DTC and high PBF/PTTG tumour
expression. (a) TCGA clinical data showing overall survival (upper) and disease-free survival (lower) curves for
BRAF-mutant DTC of different PBF and PTTG expression subsets compared to all DTC cases. P-values were
determined by the log-rank test (expression subsets: high PBF (n=20), high PTTG (n=20), high PBF/high PTTG
(n=18) and low PBF/low PTTG (n=14). (b) Pie charts summarize the neoplasm disease stage of BRAF-mutant DTC
with different PBF and PTTG expression subsets. (c) Table shows most frequently associated mutations (>10%
incidence) in BRAF-mutant DTC with high PBF and PTTG expression.
Supplementary Figure S23
Supplementary Figure S23. Lack of association between TCGA patient survival outcome and a panel of cellular
proliferation markers. TCGA clinical data showing overall survival curves for DTC with high tumoural
expression (i.e. Q4- upper quartile of gene expression in unmatched TCGA cases, n=65) of six proliferation
markers compared to all DTC cases (n=255). Proliferation markers analysed were cyclin D1, cyclin B1, bub1,
cyclin E1, e2f1 and top2a as indicated. P-values were determined by the log-rank test.
Supplementary Table S1
Supplementary Table S1. p53 target genes in gene panels. DDR genes used in study are categorised according to
type of p53 target gene. p53 target gene categories are defined as genes regulated by a p53 response element, the
p53-p21 pathway, the p53-miRNA pathway (e.g. miR-34), p53 interactions (e.g. Sp1), other putative p53 and/or
p53-lincRNA-21 regulated genes and other p21 regulated genes. 58/82 DDR genes (70.7%) were identified as a p53
target gene in gene panel #1 compared to 76/95 genes (80%) in gene panel #2. References are provided to support
categorisation of genes as p53 target genes (Supplementary References).
Supplementary Table S2. Differentially expressed genes in DTC with high PBF and PTTG
expression. Genes are ranked in order of fold-change of expression (log2 values) in human thyroid
tumours compared to matched normal thyroid tissue.
Supplementary Table S2
Supplementary Table S3
Supplementary Table S3. Primers and PCR conditions used in study. Suppliers were Alta
Bioscience, Eurogentec and ThermoFisher Scientific. PPIA and HPRT1 Taqman assays were used
in combination as internal controls.
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